Eli Lilly and Company - Depreciation and Amortization Expense

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Depreciation-and-Amortization-Expense" stands at 1.90 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Eli Lilly and Company's third quarter result of 0.47 Billion USD for the item "Depreciation and Amortization Expense" represents a decrease of -1.78 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 0.47 Billion USD for the item "Depreciation and Amortization Expense" represents an increase of 0.69 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 1.90 Billion USD for the item "Depreciation and Amortization Expense" represents an increase of 0.17 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 13.57 percent compared to the value the year prior.
The 1 year change in percent is 13.57.
The 3 year change in percent is 19.01.
The 5 year change in percent is 46.18.
The 10 year change in percent is 33.18.

The Serie's long term average value is 1.49 Billion United States Dollars. It's latest available value, on 09/30/2025, is 27.24 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2020, to it's latest available value, on 09/30/2025, is +64.92%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.